Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH 66336 and Gemcitabine in Resectable Primary Liver Neoplasms
NCT00020774Phase 2Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Oct 1998
- Primary completion
- Jan 2003
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of lonafarnib in liver cancer, sponsored by UCLA Jonsson Comprehensive Cancer Center. Planned start Oct 1998; status: withdrawn.
02
Drugs
lonafarnib
03
Conditions
liver cancer
Beyond the preview
Go deeper on NCT00020774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00020774.